Herman Goossens, MD, is a professor of Medical Microbiology at the University of Antwerp in Belgium, director of the research Laboratory of Medical Microbiology at the University of Antwerp, and director of the Laboratory of Clinical Biology of the University Hospital Antwerp. He was part-time professor at the University of Leiden from 2000-2008 and has a part-time position since 2017 at the University Medical Centre Utrecht. He received several honours and awards, including the award of the American APUA (Alliance for the Prudent Use of Antibiotics) in 2006 and the medical sciences award of the Belgian Royal Academy of Medicine for the period 2011-2015. His professional goal is to bridge the gap between basic and clinical research, with a major focus on antibiotic resistance, to enhance the standard of healthcare, public health and professional standards, for the good of the public in large. His vision is to build a sustainable infrastructure for clinical research on infectious diseases in Europe. He is a popular resource person and opinion leader, much sought after by local and international media for views on matters related to public health and infectious diseases.
MEET HERMAN GOOSSENS @ #KFG2018
Herman Goossens will give a presentation in the session "TEST New Life Sciences Solutions":
"Sustainable model to tackle antimicrobial resistance and Emerging Infectious Diseases"
The global threats of Antimicrobal Resistance (AMR) and Emerging Infectious Diseases (EID are usually considered to be distinct, which has led to relatively unlinked research infrastructures. Whereas the threat of AMR centres primarily on drug-resistant bacteria, the threat of EIDs thus far has mostly come from (zoonotic) viruses. The rate of emergence and spread also differ: there is a need for immediate action and response for EID occurring in epidemics of symptomatic infections, whereas multi drug resistant (MDR) bacteria frequently emerge as sporadic cases of symptomatic infection, slowly evolving towards endemicity of asymptomatic carriage. As a result of perceived differences, traditionally both fields of research have been addressed by different clinical networks and initiatives. Notwithstanding some differences in the expertise required at a clinical level, and even more at the pre-clinical level, essentially the clinical research response to both AMR and EID both require an efficiently operating large-scale clinical research network infrastructure that facilitates efficient clinical evaluation of patients, drugs and alternative interventions. In my presentation, I will propose a sustainable model to tackle AMR and EID